Pui-Mun Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pui-Mun Wong has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Xuejun Jiang
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
6 shared publications Anna Gan
Genome Institute of Singapore (GIS), Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore
4 shared publications- Bruno Reversade
Laboratory of Human Genetics and Therapeutics, King Abdullah University of Science and Technology, Thuwal 23955, Kingdom of Saudi Arabia
4 shared publications - Iain Beehuat Tan
Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
4 shared publications - Anders Jacobsen Skanderup
Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
3 shared publications - Ian G. Ganley
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA
3 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessComprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.
- Open Access
A Computational Framework for Analysis of cfDNA Fragmentation Profiles
Circulating cell-free DNA (cfDNA) has emerged as a promising non-invasive medium for studying tumor molecular profiles. Non-random fragmentation patterns in plasma cfDNA, particularly around nucleosome-depleted regions (NDRs) near transcription start sites (TSS), have been shown to reflect epigenetic regulation and gene expression. In this study, coverage profiles of the NDR were utilized to derive an NDR score, which was subsequently used as a proxy for inferring gene expression. To reduce transcript-to-transcript variability and enhance the clarity of these expression-associated signals, we implement a method for GC-bias correction of cfDNA samples. A computational framework (NDRDiff) was then developed to enable comparative analyses of NDR score profiles across different sample groups. The GC-bias correction preserved the overall trend of the NDR signal while improving the separation of gene expression levels, as demonstrated by comparisons of healthy donor cfDNA samples with matched blood RNA-seq data. Validation on a simulated dataset showed that NDRDiff achieved an area under the precision–recall curve (AUPRC) of 0.916, outperforming a standard t-test (AUPRC of 0.777). When applied to a comparison of healthy donor cfDNA and metastatic colorectal cancer (mCRC) cfDNA, NDRDiff identified 531 differential NDR score (DNS) genes that facilitated clear separation between the two groups. These DNS genes were found to correlate with tumor fraction estimates (down-regulated DNS genes: Pearson R = 0.89, p < 0.05; up-regulated DNS genes: Pearson R = –0.88, p < 0.05) and included CLDN4, BIN2, and IRAG2, which exhibit strong associations with colorectal cancer or blood cell expression signatures. Gene set enrichment analysis further revealed enrichment of colon and other gastrointestinal tissue signatures. Collectively, these findings underscore the potential of NDR-based cfDNA analysis as a minimally invasive tool for monitoring tumor-related molecular features in cancer.
Open AccessA Computational Framework for Analysis of cfDNA Fragmentation Profiles
Circulating cell-free DNA (cfDNA) has emerged as a promising non-invasive medium for studying tumor molecular profiles. Non-random fragmentation patterns in plasma cfDNA, particularly around nucleosome-depleted regions (NDRs) near transcription start sites (TSS), have been shown to reflect epigenetic regulation and gene expression. In this study, coverage profiles of the NDR were utilized to derive an NDR score, which was subsequently used as a proxy for inferring gene expression. To reduce transcript-to-transcript variability and enhance the clarity of these expression-associated signals, we implement a method for GC-bias correction of cfDNA samples. A computational framework (NDRDiff) was then developed to enable comparative analyses of NDR score profiles across different sample groups. The GC-bias correction preserved the overall trend of the NDR signal while improving the separation of gene expression levels, as demonstrated by comparisons of healthy donor cfDNA samples with matched blood RNA-seq data. Validation on a simulated dataset showed that NDRDiff achieved an area under the precision–recall curve (AUPRC) of 0.916, outperforming a standard t-test (AUPRC of 0.777). When applied to a comparison of healthy donor cfDNA and metastatic colorectal cancer (mCRC) cfDNA, NDRDiff identified 531 differential NDR score (DNS) genes that facilitated clear separation between the two groups. These DNS genes were found to correlate with tumor fraction estimates (down-regulated DNS genes: Pearson R = 0.89, p < 0.05; up-regulated DNS genes: Pearson R = –0.88, p < 0.05) and included CLDN4, BIN2, and IRAG2, which exhibit strong associations with colorectal cancer or blood cell expression signatures. Gene set enrichment analysis further revealed enrichment of colon and other gastrointestinal tissue signatures. Collectively, these findings underscore the potential of NDR-based cfDNA analysis as a minimally invasive tool for monitoring tumor-related molecular features in cancer.
- 7 March 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (3) , 307-319
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths
The quantification of circulating tumour DNA (ctDNA) in blood enables non-invasive surveillance of cancer progression. Here we show that a deep-learning model can accurately quantify ctDNA from the density distribution of cell-free DNA-fragment lengths. We validated the model, which we named ‘Fragle’, by using low-pass whole-genome-sequencing data from multiple cancer types and healthy control cohorts. In independent cohorts, Fragle outperformed tumour-naive methods, achieving higher accuracy and lower detection limits. We also show that Fragle is compatible with targeted sequencing data. In plasma samples from patients with colorectal cancer, longitudinal analysis with Fragle revealed strong concordance between ctDNA dynamics and treatment responses. In patients with resected lung cancer, Fragle outperformed a tumour-naive gene panel in the prediction of minimal residual disease for risk stratification. The method’s versatility, speed and accuracy for ctDNA quantification suggest that it may have broad clinical utility.
- 7 March 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (3) , 307-319
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths
The quantification of circulating tumour DNA (ctDNA) in blood enables non-invasive surveillance of cancer progression. Here we show that a deep-learning model can accurately quantify ctDNA from the density distribution of cell-free DNA-fragment lengths. We validated the model, which we named ‘Fragle’, by using low-pass whole-genome-sequencing data from multiple cancer types and healthy control cohorts. In independent cohorts, Fragle outperformed tumour-naive methods, achieving higher accuracy and lower detection limits. We also show that Fragle is compatible with targeted sequencing data. In plasma samples from patients with colorectal cancer, longitudinal analysis with Fragle revealed strong concordance between ctDNA dynamics and treatment responses. In patients with resected lung cancer, Fragle outperformed a tumour-naive gene panel in the prediction of minimal residual disease for risk stratification. The method’s versatility, speed and accuracy for ctDNA quantification suggest that it may have broad clinical utility.
- Open Access
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi0197
DARESOME enables concurrent profiling of multiple DNA modifications with restriction enzymes in single cells and cell-free DNA
5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are the most abundant DNA modifications that have important roles in gene regulation. Detailed studies of these different epigenetic marks aimed at understanding their combined effects and dynamic interconversion are, however, hampered by the inability of current methods to simultaneously measure both modifications, particularly in samples with limited quantities. We present DNA analysis by restriction enzyme for simultaneous detection of multiple epigenomic states (DARESOME), an assay based on modification-sensitive restriction digest and sequential tag ligation that can concurrently perform quantitative profiling of unmodified cytosine, 5mC, and 5hmC in CCGG sites genome-wide. DARESOME reveals the opposing roles of 5mC and 5hmC in gene expression regulation as well as their interconversion during aging in mouse brain. Implementation of DARESOME in single cells demonstrates pronounced 5hmC strand bias that reflects the semiconservative replication of DNA. Last, we showed that DARESOME enables integrative genomic, 5mC, and 5hmC profiling of cell-free DNA that uncovered multiomics cancer signatures in liquid biopsy.
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi0197
Open AccessDARESOME enables concurrent profiling of multiple DNA modifications with restriction enzymes in single cells and cell-free DNA
5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are the most abundant DNA modifications that have important roles in gene regulation. Detailed studies of these different epigenetic marks aimed at understanding their combined effects and dynamic interconversion are, however, hampered by the inability of current methods to simultaneously measure both modifications, particularly in samples with limited quantities. We present DNA analysis by restriction enzyme for simultaneous detection of multiple epigenomic states (DARESOME), an assay based on modification-sensitive restriction digest and sequential tag ligation that can concurrently perform quantitative profiling of unmodified cytosine, 5mC, and 5hmC in CCGG sites genome-wide. DARESOME reveals the opposing roles of 5mC and 5hmC in gene expression regulation as well as their interconversion during aging in mouse brain. Implementation of DARESOME in single cells demonstrates pronounced 5hmC strand bias that reflects the semiconservative replication of DNA. Last, we showed that DARESOME enables integrative genomic, 5mC, and 5hmC profiling of cell-free DNA that uncovered multiomics cancer signatures in liquid biopsy.
- 19 September 2022
- Published by Morressier GmbH
ESDR176 - C10orf99/2610528A11Rik induces keratinocyte proinflammatory response and regulates lipid metabolism and barrier formation of the skin
The protective machinery of the skin opposes external agents by barrier and innate and adaptive immunity. The local interplay in the epithelial-i | POSTER
- 19 September 2022
- Published by Morressier GmbH
ESDR176 - C10orf99/2610528A11Rik induces keratinocyte proinflammatory response and regulates lipid metabolism and barrier formation of the skin
The protective machinery of the skin opposes external agents by barrier and innate and adaptive immunity. The local interplay in the epithelial-i | POSTER
- Open Access
- 9 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (36) , eabn4030
Heat selection enables highly scalable methylome profiling in cell-free DNA for noninvasive monitoring of cancer patients
Genome-wide analysis of cell-free DNA methylation profile is a promising approach for sensitive and specific detection of many cancers. However, scaling such assays for clinical translation is impractical because of the high cost of whole-genome bisulfite sequencing. We show that the small fraction of GC-rich genome is highly enriched in CpG sites and disproportionately harbors most of the cancer-specific methylation signature. Here, we report on the simple and effective heat enrichment of CpG-rich regions for bisulfite sequencing (Heatrich-BS) platform that allows for focused methylation profiling in these highly informative regions. Our novel method and bioinformatics algorithm enable accurate tumor burden estimation and quantitative tracking of colorectal cancer patient’s response to treatment at much reduced sequencing cost suitable for frequent monitoring. We also show tumor epigenetic subtyping using Heatrich-BS, which could enable patient stratification. Heatrich-BS holds great potential for highly scalable screening and monitoring of cancer using liquid biopsy.
- 9 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (36) , eabn4030
Open AccessHeat selection enables highly scalable methylome profiling in cell-free DNA for noninvasive monitoring of cancer patients
Genome-wide analysis of cell-free DNA methylation profile is a promising approach for sensitive and specific detection of many cancers. However, scaling such assays for clinical translation is impractical because of the high cost of whole-genome bisulfite sequencing. We show that the small fraction of GC-rich genome is highly enriched in CpG sites and disproportionately harbors most of the cancer-specific methylation signature. Here, we report on the simple and effective heat enrichment of CpG-rich regions for bisulfite sequencing (Heatrich-BS) platform that allows for focused methylation profiling in these highly informative regions. Our novel method and bioinformatics algorithm enable accurate tumor burden estimation and quantitative tracking of colorectal cancer patient’s response to treatment at much reduced sequencing cost suitable for frequent monitoring. We also show tumor epigenetic subtyping using Heatrich-BS, which could enable patient stratification. Heatrich-BS holds great potential for highly scalable screening and monitoring of cancer using liquid biopsy.
- 2 June 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3729-3740
RABENOSYN separation-of-function mutations uncouple endosomal recycling from lysosomal degradation, causing a distinct Mendelian disorder
Rabenosyn (RBSN) is a conserved endosomal protein necessary for regulating internalized cargo. Here, we present clinical, genetic, cellular and biochemical evidence that two distinct RBSN missense variants are responsible for a novel Mendelian disorder consisting of progressive muscle weakness, facial dysmorphisms, ophthalmoplegia and intellectual disability. Using exome sequencing, we identified recessively acting germline alleles p.Arg180Gly and p.Gly183Arg, which are both situated in the FYVE domain of RBSN. We find that these variants abrogate binding to its cognate substrate phosphatidylinositol 3-phosphate (PI3P) and thus prevent its translocation to early endosomes. Although the endosomal recycling pathway was unaltered, mutant p.Gly183Arg patient fibroblasts show accumulation of cargo tagged for lysosomal degradation. Our results suggest that these variants are separation-of-function alleles, which cause a delay in endosomal maturation without affecting cargo recycling. We conclude that distinct germline mutations in RBSN cause non-overlapping phenotypes with specific and discrete endolysosomal cellular defects.
- 2 June 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3729-3740
RABENOSYN separation-of-function mutations uncouple endosomal recycling from lysosomal degradation, causing a distinct Mendelian disorder
Rabenosyn (RBSN) is a conserved endosomal protein necessary for regulating internalized cargo. Here, we present clinical, genetic, cellular and biochemical evidence that two distinct RBSN missense variants are responsible for a novel Mendelian disorder consisting of progressive muscle weakness, facial dysmorphisms, ophthalmoplegia and intellectual disability. Using exome sequencing, we identified recessively acting germline alleles p.Arg180Gly and p.Gly183Arg, which are both situated in the FYVE domain of RBSN. We find that these variants abrogate binding to its cognate substrate phosphatidylinositol 3-phosphate (PI3P) and thus prevent its translocation to early endosomes. Although the endosomal recycling pathway was unaltered, mutant p.Gly183Arg patient fibroblasts show accumulation of cargo tagged for lysosomal degradation. Our results suggest that these variants are separation-of-function alleles, which cause a delay in endosomal maturation without affecting cargo recycling. We conclude that distinct germline mutations in RBSN cause non-overlapping phenotypes with specific and discrete endolysosomal cellular defects.
- Open Access
- 29 October 2018
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 10 (5) , 376-381
Unc-51-like kinase (ULK) complex-independent autophagy induced by hypoxia
- 29 October 2018
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 10 (5) , 376-381
Open AccessUnc-51-like kinase (ULK) complex-independent autophagy induced by hypoxia
- 1 February 2018
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 138 (2) , 291-300
ENPP1 Mutation Causes Recessive Cole Disease by Altering Melanogenesis
- 1 February 2018
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 138 (2) , 291-300
ENPP1 Mutation Causes Recessive Cole Disease by Altering Melanogenesis
- 1 July 2017
- Published by Elsevier in Mechanisms of Development
- Vol. 145, S38
Reto: A Novel Secreted Peptide in the Skin
- 1 July 2017
- Published by Elsevier in Mechanisms of Development
- Vol. 145, S38
Reto: A Novel Secreted Peptide in the Skin